Home / IMMUNITYBIO, INC. (IBRX)

IMMUNITYBIO, INC. (IBRX) Technical Analysis

Updated: 2026-06-16 09:31 UTC · Last close: 7.13 (+0.42%) · Support: 5.84 · Resistance: 7.46
IMMUNITYBIO, INC. (IBRX) technical analysis page covering price structure, support and resistance, momentum conditions and a fundamentals snapshot from WOI Scanner.
⬇️ Support
5.84
⬆️ Resistance
7.46
🚀 Bullish Trigger
a clean close above 7.46 would strengthen the upside continuation case.
🔺 Technical Setup
Pattern
Triangle Compression / SYM / DOWN
State
Forming
Breakout Watch
Downtrend line not broken yet · score 6
Watch Level
7.55
Compression
15%
RSI(14)
44.8
🎯 Decision Map
From a roadmap perspective, the setup is boxed by support near 5.85 and resistance around 7.46. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
📊 Technical Summary
At a glance
Trend
Mixed
Momentum
Neutral
Range
54% of 52W range
Key Zone
5.84 / 7.46
IMMUNITYBIO, INC. (IBRX) closed at 7.13 (+0.42%). Medium-term tone has softened, but price remains above MA200. Momentum remains weak (-10.54%), with 52W position: 53% of range, while Volatility: ATR14 5.50%. RSI(14) is 44.8, leaving momentum in a fairly neutral range. RSI has been trending higher in recent sessions, indicating improving momentum conditions. MACD remains below its signal line, which shows that momentum confirmation is still limited.
🔺
Setup: Pattern Triangle compression remains the main pattern under review.
🎯
Key levels: Key levels The nearest decision zone is framed by support at 5.84 and resistance at 7.46.
⚠️
Risk: A move through resistance would improve the short-term technical tone, while a loss of support would weaken the current structure.
💼 Fundamentals Snapshot
Source: sec
💼 Business Lens
QUALITY VIEW
Financial quality snapshot
Financial context is mixed
📈 Growth: Strong 💰 Profit: Negative 💵 Cash: Mixed 🛡 Balance: Manageable
• Quarterly revenue growth remains strong and still points upward.
• Quarterly profitability remains weak, with net margin below zero.
💵 Revenue
44.21M
📈 Net Income
-632.80M
🧮 EPS (Basic)
-0.62
🏢 Company
IMMUNITYBIO, INC.
🏷 Sector
Healthcare
🧩 Industry
Biotech
Compare with related stocks
Same sector and industry ideas for deeper research
Amgen (AMGN) technical analysisAxsome Therapeutics (AXSM) technical analysisBeam Therapeutics (BEAM) technical analysisCRISPR Therapeutics AG (CRSP) technical analysisAmicus Therapeutics (FOLD) technical analysisImmunome (IMNM) technical analysisAbbVie (ABBV) technical analysis
WOI OPEN ADVANCED ANALYSIS WORKSPACE
Note: This is an algorithmic technical snapshot (not financial advice).
IBRX Chart